GSK has been the topic of several other reports. StockNews.com downgraded GSK from a strong-buy rating to a buy rating in a research report on Thursday, September 8th. Morgan Stanley reduced their target price on GSK from GBX 1,860 ($22.47) to GBX 1,550 ($18.73) in a research report on Wednesday, September 7th. TheStreet downgraded GSK from a b rating to a c+ rating in a research report on Monday, August 29th. Jefferies Financial Group downgraded GSK from a buy rating to a hold rating in a research report on Thursday, September 8th. Finally, AlphaValue downgraded GSK to a reduce rating in a research report on Tuesday, July 19th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, GSK presently has a consensus rating of Hold and an average target price of $1,700.00.
GSK Stock Down 0.6 %
GSK stock opened at $31.02 on Thursday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.31 and a current ratio of 1.43. GSK has a fifty-two week low of $30.83 and a fifty-two week high of $46.97. The stock’s fifty day moving average is $37.40 and its two-hundred day moving average is $41.40. The firm has a market capitalization of $63.08 billion, a price-to-earnings ratio of 10.27, a price-to-earnings-growth ratio of 1.20 and a beta of 0.61.
GSK Increases Dividend
Institutional Investors Weigh In On GSK
A number of large investors have recently modified their holdings of GSK. Tyler Stone Wealth Management acquired a new stake in GSK during the 4th quarter valued at approximately $26,000. Tsfg LLC grew its stake in GSK by 67.9% during the 1st quarter. Tsfg LLC now owns 618 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 250 shares in the last quarter. Glassman Wealth Services grew its stake in GSK by 71.3% during the 4th quarter. Glassman Wealth Services now owns 627 shares of the pharmaceutical company’s stock valued at $28,000 after purchasing an additional 261 shares in the last quarter. Castle Wealth Management LLC acquired a new stake in GSK during the 2nd quarter valued at approximately $28,000. Finally, Toth Financial Advisory Corp acquired a new stake in GSK during the 1st quarter valued at approximately $30,000. Institutional investors and hedge funds own 16.86% of the company’s stock.
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Get a free copy of the StockNews.com research report on GSK (GSK)
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It’s a Down Week
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.